TherapeuticsMD (NASDAQ:TXMD) Posts Quarterly Earnings Results, Beats Expectations By $6.13 EPS

TherapeuticsMD (NASDAQ:TXMD) announced its earnings results on Tuesday. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13, FiscalAI reports. TherapeuticsMD had a return on equity of 0.32% and a net margin of 5.34%.The company had revenue of $0.87 million during the quarter, compared to analyst estimates of $19.77 million.

TherapeuticsMD Price Performance

TherapeuticsMD stock remained flat at $2.07 during mid-day trading on Tuesday. The company had a trading volume of 14,514 shares, compared to its average volume of 50,144. The firm’s 50 day moving average is $2.04 and its 200-day moving average is $2.14. The firm has a market cap of $23.95 million, a PE ratio of 34.50 and a beta of 0.61. TherapeuticsMD has a fifty-two week low of $0.99 and a fifty-two week high of $2.95.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of TherapeuticsMD in a research report on Thursday, July 2nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TherapeuticsMD stock. Citadel Advisors LLC increased its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,273 shares of the company’s stock after buying an additional 19,073 shares during the period. Citadel Advisors LLC owned 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent quarter. 30.74% of the stock is owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.